The Molecular Imaging discipline supports small and large molecule drug development through the application of translational, nuclear imaging, quantitative autoradiography and radiopharmaceutical production. Primary translational, nuclear imaging platforms and other applicable imaging platforms consist of Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) platforms. Primary radiopharmaceutical production efforts are focused on development of novel and industry standard automated and manual radiolabeling and production methods to enable in vivo and ex vivo imaging to assess differing parameters of small and large molecules using applicable radioisotopes, such as: 11C, 18F, 64Cu, 68Ga, 89Zr, 99mTc, 111In, 123I, 124I, 125I, 131I, 177Lu, 203Pb, etc. Utilizing these platforms/assays, the team is for execution of preclinical studies in small and large animal models in both regulated and non regulated preclinical studies.